Critical Analysis: PerkinElmer (PKI) vs. Natus Medical (BABY)
PerkinElmer (NYSE: PKI) and Natus Medical (NASDAQ:BABY) are both computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
Earnings & Valuation
This table compares PerkinElmer and Natus Medical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|PerkinElmer||$2.14 billion||3.69||$416.05 million||$3.31||21.67|
|Natus Medical||$445.49 million||2.93||$48.00 million||$0.57||70.35|
PerkinElmer has higher revenue and earnings than Natus Medical. PerkinElmer is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.
PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. Natus Medical does not pay a dividend. PerkinElmer pays out 8.5% of its earnings in the form of a dividend.
This table compares PerkinElmer and Natus Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
PerkinElmer has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.
This is a summary of recent ratings and target prices for PerkinElmer and Natus Medical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PerkinElmer presently has a consensus price target of $67.69, indicating a potential downside of 5.63%. Natus Medical has a consensus price target of $48.00, indicating a potential upside of 19.70%. Given Natus Medical’s higher probable upside, analysts plainly believe Natus Medical is more favorable than PerkinElmer.
Institutional and Insider Ownership
91.5% of PerkinElmer shares are held by institutional investors. Comparatively, 92.7% of Natus Medical shares are held by institutional investors. 2.2% of PerkinElmer shares are held by company insiders. Comparatively, 5.5% of Natus Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
PerkinElmer beats Natus Medical on 9 of the 16 factors compared between the two stocks.
PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics.
Receive News & Stock Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related stocks with our FREE daily email newsletter.